Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin.

Autor: Healy D; Department of Family Medicine, McMaster University, Hamilton, ON, Canada., Bahrick A; University Counseling Service, University of Iowa, Iowa City, IA, USA., Bak M; Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands.; FACT, Mondriaan Mental Health, Maastricht/Heerlen, The Netherlands., Barbato A; Unit for Quality of Care and Rights Promotion in Mental Health, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy., Calabrò RS; IRCCS Centro Neurolesi Bonino-Pulejo, Messina, Italy., Chubak BM; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Cosci F; Department of Psychiatry and Neuropsychology, Maastricht University, Maastricht, The Netherlands.; Department of Health Sciences, University of Florence, Florence, Italy.; Clinical Pharmacopsychology Laboratory, University of Florence, Florence, Italy., Csoka AB; Department of Anatomy, Howard University College of Medicine, Washington, DC, USA., D'Avanzo B; Unit for Quality of Care and Rights Promotion in Mental Health, IRCCS Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy., Diviccaro S; Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy., Giatti S; Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy., Goldstein I; Alvarado Hospital, San Diego, CA, USA.; San Diego Sexual Medicine, San Diego, CA, USA., Graf H; Department of Psychiatry and Psychotherapy, Ulm University, Ulm, Germany., Hellstrom WJG; Department of Urology, Tulane University School of Medicine, New Orleans, LA, USA., Irwig MS; Beth Israel Deaconess Medical Center, Boston, MA, USA.; Harvard Medical School, Boston, MA, USA., Jannini EA; Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy., Janssen PKC; Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Centre, Maastricht, The Netherlands.; Department of Hospital Pharmacy, VieCuri Medical Center, Venlo, The Netherlands., Khera M; Department of Urology, Baylor School of Medicine, Houston, TX, USA., Kumar MT; Institute for Mind and Brain, Kerala, India., Le Noury J; North Wales Department of Psychological Medicine, Bangor, Wales, UK., Lew-Starowicz M; Department of Psychiatry, Centre of Postgraduate Medical Education, Warsaw, Poland., Linden DEJ; Department of Psychiatry and Neuropsychology, Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Maastricht University, Maastricht, The Netherlands., Lüning C; Department of Psychology and Psychotherapy, Witten/Herdecke University, Witten, Germany., Mangin D; Department of Family Medicine, McMaster University, Hamilton, ON, Canada., Melcangi RC; Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy., Rodríguez OWMAAS; Psychiatry Service, Hospital Universitario San Agustín, Avilés, Asturias, Spain., Panicker JN; Department of Uro-Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.; Department of Brain Repair and Rehabilitation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK., Patacchini A; Department of Health Sciences, University of Florence, Florence, Italy., Pearlman AM; Carver College of Medicine, University of Iowa Health Care, Iowa City, IA, USA., Pukall CF; Department of Psychology, Queen's University, Kingston, ON, Canada., Raj S; Faculty of Social and Behavioural Sciences, Utrecht University, Utrecht, The Netherlands., Reisman Y; Flare-Health, Amstelveen, The Netherlands., Rubin RS; Department of Urology, Georgetown University School of Medicine, Washington, DC, USA., Schreiber R; Department of Neuropsychology and Psychopharmacology, Faculty of Psychology and Neuroscience, Maastricht University, Maastricht, The Netherlands., Shipko S; Private Practice, Pasadena, CA, USA., Vašečková B; Psychiatric Clinic, Slovak Medical University and University Hospital, Bratislava, Slovakia., Waraich A; San Diego Sexual Medicine, San Diego, CA, USA.
Jazyk: angličtina
Zdroj: The International journal of risk & safety in medicine [Int J Risk Saf Med] 2022; Vol. 33 (1), pp. 65-76.
DOI: 10.3233/JRS-210023
Abstrakt: Background: A set of enduring conditions have been reported in the literature involving persistent sexual dysfunction after discontinuation of serotonin reuptake inhibiting antidepressants, 5 alpha-reductase inhibitors and isotretinoin.
Objective: To develop diagnostic criteria for post-SSRI sexual dysfunction (PSSD), persistent genital arousal disorder (PGAD) following serotonin reuptake inhibitors, post-finasteride syndrome (PFS) and post-retinoid sexual dysfunction (PRSD).
Methods: The original draft was designed using data from two published case series (Hogan et al., 2014 and Healy et al., 2018), which represent the largest public collections of data on these enduring conditions. It was further developed with the involvement of a multidisciplinary panel of experts.
Results: A set of criteria were agreed upon for each of the above conditions. Features of PSSD, PFS and PRSD commonly include decreased genital and orgasmic sensation, decreased sexual desire and erectile dysfunction. Ancillary non-sexual symptoms vary depending on the specific condition but can include emotional blunting and cognitive impairment. PGAD presents with an almost mirror image of unwanted sensations of genital arousal or irritability in the absence of sexual desire. A new term, post-SSRI asexuality, is introduced to describe a dampening of sexual interest and pleasure resulting from a pre-natal or pre-teen exposure to a serotonin reuptake inhibitor.
Conclusions: These criteria will help in both clinical and research settings. As with all criteria, they will likely need modification in the light of developments.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje